https://www.basilea.com/news/news/basilea-finanzkennzahlen-2012-solider-bestand-liquider-mittel-wichtige-anstehende-meilensteine 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-2012-financials-with-a-solid-cash-position-and-significant-milestones-ahead 2021-07-13T16:14:22+02:00 0.5 https://www.basilea.com/news/news/basilea-receives-request-to-place-repayment-of-chf-48-million-from-capital-contribution-reserve-on-the-agenda-of-the-ordinary-general-meeting-of-shareholders 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-traktandierungsbegehren-fuer-ordentliche-generalversammlung-hinsichtlich-rueckzahlung-von-chf-48-mio-aus-der-reserve-aus-kapitaleinlagen 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basileas-board-proposes-martin-nicklasson-to-succeed-chairman-werner-henrich-and-recommends-to-shareholders-that-they-do-not-support-the-request-for-a-capital-distribution-at-this-time 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basileas-verwaltungsrat-schlaegt-martin-nicklasson-als-nachfolger-von-vr-praesident-werner-henrich-vor-und-empfiehlt-den-aktionaeren-den-antrag-auf-kapitalausschuettung-derzeit-nicht-zu-unterstuetzen 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/resolutions-of-the-ordinary-general-meeting-of-shareholders-of-basilea-pharmaceutica-ltd-1 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/beschluesse-der-ordentlichen-generalversammlung-der-basilea-pharmaceutica-ag-1 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-new-data-on-anti-infective-drug-candidates-addressing-drug-resistance 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-informiert-ueber-praesentation-neuer-daten-zu-medikamentenkandidaten-gegen-infektionen-durch-resistente-krankheitserreger 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-erteilung-des-orphan-drug-status-fuer-isavuconazol-durch-die-us-arzneimittelbehoerde-fda-bekannt 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-isavuconazole-orphan-drug-designation-by-us-fda 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-presents-first-phase-1-data-from-its-novel-anti-cancer-drug-bal101553-at-asco-conference 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-erste-phase-1-daten-fuer-ihren-neuartigen-antikrebs-wirkstoff-bal101553-auf-asco-konferenz 2021-10-14T18:41:18+02:00 0.5 https://www.basilea.com/news/news/basilea-awarded-contract-by-barda-of-up-to-usd-89-million-for-the-development-of-its-novel-antibiotic-bal30072 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-barda-vertrag-in-hoehe-von-bis-zu-usd-89-mio-fuer-die-entwicklung-ihres-neuartigen-antibiotikums-bal30072 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-provides-update-on-isavuconazole-phase-3-program 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-update-zu-isavuconazol-phase-3-programm 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-2013-half-year-financials-with-improved-operating-results 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-veroeffentlicht-halbjahres-finanzzahlen-2013-mit-verbessertem-operativen-ergebnis 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-19-posters-at-icaac-on-investigational-anti-infectives-isavuconazole-ceftobiprole-and-bal30072 2020-06-29T09:54:22+02:00 0.5 https://www.basilea.com/news/news/basilea-praesentation-von-19-postern-zu-anti-infektiva-produktkandidaten-isavuconazol-ceftobiprol-und-bal30072-auf-icaac 2020-06-29T09:54:34+02:00 0.5 https://www.basilea.com/news/news/swissmedic-accepts-for-review-basileas-ceftobiprole-marketing-authorization-application-for-the-treatment-of-pneumonia 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/swissmedic-nimmt-basileas-zulassungsantrag-fuer-ceftobiprol-zur-behandlung-von-lungenentzuendung-zur-pruefung-an 2019-01-04T15:41:24+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-positive-topline-phase-3-results-for-antifungal-isavuconazole 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-veroeffentlicht-positive-topline-ergebnisse-aus-phase-3-studie-mit-antimykotikum-isavuconazol 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-antibiotikum-ceftobiprol-erhaelt-in-europa-zulassung-fuer-die-behandlung-von-lungenentzuendungen 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-antibiotic-ceftobiprole-obtains-regulatory-approval-in-europe-for-pneumonia 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-appoints-new-chief-financial-officer 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-ernennt-neuen-chief-financial-officer 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-erteilung-des-orphan-drug-status-fuer-isavuconazol-zur-behandlung-von-zygomykose-durch-die-us-arzneimittelbehoerde-fda-bekannt 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-isavuconazole-orphan-drug-designation-for-treatment-of-zygomycosis-by-us-fda 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-isavuconazole-receives-qualified-infectious-disease-product-qidp-designation-from-us-fda-for-the-treatment-of-invasive-aspergillosis 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-isavuconazol-von-der-us-arzneimittelbehoerde-fda-den-qidp-status-zur-behandlung-invasiver-aspergillose-erhalten-hat 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-2013-bedeutende-meilensteine-erreicht-solide-finanzzahlen 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-2013-full-year-results-strong-operational-and-financial-performance 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-isavuconazole-receives-qualified-infectious-disease-product-designation-from-us-fda-for-the-treatment-of-invasive-mucormycosis 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-isavuconazol-von-der-us-arzneimittelbehoerde-fda-den-qidp-status-zur-behandlung-invasiver-mucormykose-erhalten-hat 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-tauscht-isavuconazol-kopromotionsrechte-in-nordamerika-gegen-volle-rechte-an-isavuconazol-in-allen-maerkten-ausserhalb-nordamerikas 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-swaps-its-isavuconazole-north-american-co-promote-rights-for-full-isavuconazole-rights-outside-of-north-america 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-oncology-drug-candidate-bal101553-demonstrates-broad-antitumor-activity-in-treatment-resistant-breast-cancer-models-as-presented-at-aacr 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-auf-aacr-konferenz-daten-zur-breiten-antitumor-aktivitaet-ihres-onkologie-medikamentenkandidaten-bal101553-in-modellen-fuer-behandlungsresistenten-brustkrebs 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/beschluesse-der-ordentlichen-generalversammlung-der-basilea-pharmaceutica-ag 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/resolutions-of-the-ordinary-general-meeting-of-shareholders-of-basilea-pharmaceutica-ltd 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-presents-new-data-on-its-antibiotics-pipeline-at-eccmid 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-auf-eccmid-neue-daten-zu-antibiotika-aus-ihrer-entwicklungspipeline 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-weitere-daten-aus-positiver-isavconazol-phase-3-studie-secure-auf-eccmid 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-additional-data-on-positive-isavuconazole-phase-3-secure-study-at-eccmid 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-oncology-drug-candidate-bal101553-shows-first-evidence-of-antitumor-activity-in-phase-1-study 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-krebsmedikamentenkandidat-bal101553-zeigt-in-phase-1-studie-erste-hinweise-auf-antitumorwirkung 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-beginnt-phase-1-kombinationsstudie-mit-ihrem-gramnegativen-antibiotikum-bal30072-und-meropenem-1 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-initiates-phase-1-combination-study-with-its-gram-negative-antibiotic-bal30072-and-meropenem-1 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-initiates-phase-1-combination-study-with-its-gram-negative-antibiotic-bal30072-and-meropenem 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-beginnt-phase-1-kombinationsstudie-mit-ihrem-gramnegativen-antibiotikum-bal30072-und-meropenem 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-provides-update-on-ceftobiproles-us-regulatory-status 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-informiert-ueber-den-zulassungsstatus-von-ceftobiprol-in-den-usa 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-startet-phase-2a-studie-mit-ihrem-krebsmedikamentenkandidaten-bal101553 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-start-of-phase-2a-study-with-oncology-drug-candidate-bal101553 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-partner-astellas-submits-isavuconazole-us-nda-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-partner-astellas-reicht-us-zulassungsantrag-fuer-isavuconazol-zur-behandlung-von-invasiver-aspergillose-und-invasiver-mucormykose-ein 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basileas-isavuconazol-erhaelt-in-europa-orphan-drug-status-zur-behandlung-invasiver-schimmelpilzinfektionen 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-isavuconazole-receives-orphan-drug-designations-in-europe-for-the-treatment-of-invasive-mold-infections 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-isavuconazole-received-qidp-designation-from-us-fda-for-the-treatment-of-invasive-candidiasis 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-isavuconazol-von-der-us-arzneimittelbehoerde-fda-den-qidp-status-zur-behandlung-invasiver-candida-infektionen-erhalten-hat 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reicht-europaeischen-zulassungsantrag-fuer-isavuconazol-zur-behandlung-invasiver-schimmelpilzinfektionen-ein 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-submits-isavuconazole-european-marketing-authorization-application-for-the-treatment-of-invasive-mold-infections 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-to-launch-zevterar-mabelior-ceftobiprole-medocaril-in-europe-through-a-commercial-services-provider 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/markteinfuehrung-von-basileas-zevterar-mabelior-ceftobiprol-medocaril-in-europa-wird-ueber-einen-vertriebsdienstleister-erfolgen 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-2014-half-year-financials-ceftobiprole-launch-in-germany-planned-for-second-half-of-2014 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-halbjahreszahlen-2014-bekannt-markteinfuehrung-von-ceftobiprol-in-deutschland-im-zweiten-halbjahr-2014-geplant 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-ernennt-chief-commercial-officer 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/basilea-appoints-chief-commercial-officer 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/european-medicines-agency-accepts-basileas-isavuconazole-marketing-authorization-application-for-review 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/europaeische-arzneimittelagentur-nimmt-basileas-zulassungsantrag-fuer-isavuconazol-zur-pruefung-an 2019-01-04T15:39:43+01:00 0.5 https://www.basilea.com/news/news/praesentation-umfangreicher-daten-zu-basileas-anti-infektiva-isavuconazol-ceftobiprol-und-bal30072-auf-icaac 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/extensive-data-presented-on-basileas-anti-infectives-isavuconazole-ceftobiprole-and-bal30072-at-icaac 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basileas-partner-astellas-receives-notification-from-us-fda-of-acceptance-of-filing-of-isavuconazole-nda-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/us-fda-informiert-basileas-partner-astellas-dass-der-zulassungsantrag-fuer-isavuconazol-zur-behandlung-invasiver-aspergillose-und-mucormykose-zur-pruefung-angenommen-wurde 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-weiterer-subgruppen-und-gesundheitsoekonomischer-analysen-der-isavuconazol-phase-3-studien-auf-idweek-konferenz 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-further-subgroup-and-health-economic-analyses-of-isavuconazole-phase-3-studies-will-be-presented-at-idweek-conference 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-protocol-amendment-resulting-in-earlier-completion-of-isavuconazole-phase-3-invasive-candidiasis-study 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-studienprotokoll-aenderung-fuer-frueheren-abschluss-der-isavuconazol-phase-3-studie-zur-behandlung-von-invasiver-candidiasis 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-isavuconazol-in-den-usa-den-orphan-drug-status-zur-behandlung-invasiver-candida-infektionen-erhalten-hat 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-granting-of-us-orphan-drug-designation-to-isavuconazole-for-the-treatment-of-invasive-candidiasis 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basileas-oncology-drug-candidate-bal101553-induces-significant-anti-tumor-effect-in-treatment-refractory-tumor-models 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basileas-krebsmedikamentenkandidat-bal101553-induziert-erhebliche-antitumorwirkung-in-behandlungsresistenten-tumormodellen 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-die-fda-das-sitzungsdatum-des-beratungsausschusses-zum-us-zulassungsantrag-fuer-isavuconazol-zur-behandlung-von-invasiver-aspergillose-und-mucormykose-festgelegt-hat 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-us-fda-sets-date-of-advisory-committee-meeting-on-isavuconazole-nda-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-launch-of-antibiotic-zevterar-ceftobiprole-medocaril-in-germany 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-markteinfuehrung-von-antibiotikum-zevterar-ceftobiprolmedocaril-in-deutschland-bekannt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/swissmedic-approves-basileas-antibiotic-zevterar-ceftobiprole-medocaril-for-the-treatment-of-pneumonia 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/swissmedic-erteilt-basileas-antibiotikum-zevterar-ceftobiprol-medocaril-die-zulassung-zur-behandlung-von-lungenentzuendung 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-fda-beratungsausschuss-fuer-antiinfektiva-die-zulassung-von-isavuconazol-zur-behandlung-invasiver-aspergillose-und-mucormykose-empfiehlt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-that-fdas-anti-infective-drugs-advisory-committee-recommends-approval-of-isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-mit-soliden-ergebnissen-fuer-das-geschaeftsjahr-2014-grundlage-fuer-vermarktung-von-zevterar-in-europa-gelegt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-solid-2014-full-year-results-preparing-the-ground-for-commercialization-of-zevterar-in-europe 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-us-fda-approval-of-isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-die-us-fda-isavuconazol-die-marktzulassung-zur-behandlung-invasiver-aspergillose-und-invasiver-mucormykose-erteilt-hat 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-lizenziert-zielgerichtete-krebstherapie-ein 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-in-licenses-targeted-cancer-therapy 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-eccmid 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-kuendigt-praesentation-von-daten-zu-isavuconazol-und-ceftobiprol-auf-eccmid-an 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-ordentlicher-generalversammlung-alle-antraege-des-verwaltungsrats-3 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-resolutions-proposed-by-the-board-of-directors-at-the-ordinary-general-meeting-of-shareholders-2 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-start-of-first-in-human-phase-1-oncology-study-with-oral-panraf-kinase-inhibitor 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-start-der-ersten-phase-1-studie-mit-oralem-panraf-kinase-inhibitor-bei-krebspatienten-bekannt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-startet-klinische-phase-1-2a-onkologie-studie-mit-oral-verabreichtem-tumor-checkpoint-controller-bal101553 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-initiates-phase-1-2a-oncology-study-with-oral-formulation-of-tumor-checkpoint-controller-bal101553 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-chmp-zulassungsempfehlung-fuer-isavuconazol-cresembar-zur-behandlung-invasiver-aspergillose-und-mukormykose-in-der-europaeischen-union 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-that-chmp-recommends-approval-of-isavuconazole-cresembar-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-european-union 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-topline-results-of-isavuconazole-phase-3-study-in-candidemia-and-other-invasive-candida-infections 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-topline-daten-aus-isavuconazol-phase-3-studie-zur-behandlung-von-candidaemie-und-anderer-invasiver-candida-infektionen-bekannt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-ceftobiprol-von-der-us-arzneimittelbehoerde-fda-den-qidp-status-zur-behandlung-von-lungenentzuendungen-und-hautinfektionen-erhalten-hat 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-ceftobiprole-received-qidp-designation-from-us-fda-for-the-treatment-of-lung-and-skin-infections 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-halbjahresergebnisse-2015-wichtige-meilensteine-fuer-cresembar-und-zevterar-erreicht 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-2015-half-year-results-major-milestones-achieved-for-cresembar-and-zevterar 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basileas-chief-technology-officer-dr-ingrid-heinze-krauss-to-retire-and-dr-guenter-ditzinger-named-as-successor 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basileas-chief-technology-officer-dr-ingrid-heinze-krauss-wird-in-den-ruhestand-treten-dr-guenter-ditzinger-als-nachfolger-benannt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-entwicklung-einer-inhalierbaren-darreichungsform-ihres-gramnegativen-antibiotikums-bal30072-im-rahmen-des-europaeischen-iabc-programms-bekannt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-development-of-inhaled-dosage-form-of-its-gram-negative-antibiotic-bal30072-as-part-of-european-iabc-program 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-that-health-canada-approved-zevterar-for-the-treatment-of-bacterial-lung-infections 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-zulassung-von-zevterar-durch-health-canada-zur-behandlung-bakterieller-lungenentzuendungen-bekannt 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-signs-exclusive-distribution-agreement-for-zevterar-ceftobiprole-medocaril-in-the-middle-east-and-north-africa-with-hikma-pharmaceuticals-llc 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-unterzeichnet-exklusive-vertriebsvereinbarung-mit-hikma-pharmaceuticals-llc-fuer-zevterar-ceftobiprol-medocaril-im-nahen-osten-und-nordafrika 2019-01-04T15:38:17+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-that-european-commission-approves-isavuconazole-cresembar-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-european-union 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-die-europaeische-kommission-isavuconazol-cresembar-die-marktzulassung-zur-behandlung-von-invasiver-aspergillose-und-mukormykose-in-der-europaeischen-union-erteilt-hat 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reicht-registration-statement-fuer-geplantes-emissionsangebot-in-den-usa-ein 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-filing-of-registration-statement-for-a-proposed-offering-in-the-united-states 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-that-european-commission-maintained-isavuconazoles-orphan-drug-status 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-aufrechterhaltung-des-orphan-drug-status-von-isavuconazol-durch-die-europaeische-kommission-bekannt 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-to-present-preclinical-brain-tumor-stem-cell-data-on-its-oncology-drug-candidate-bal101553 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-praeklinische-daten-aus-studien-mit-hirntumor-stammzellen-mit-ihrem-krebsmedikamenten-kandidaten-bal101553 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-lanciert-eine-wandelanleihe 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-launches-a-senior-convertible-bond-issue 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-successfully-places-chf-200-million-senior-convertible-bonds-1 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-platziert-erfolgreich-eine-wandelanleihe-im-betrag-von-chf-200-millionen-1 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-successfully-places-chf-200-million-senior-convertible-bonds 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-platziert-erfolgreich-eine-wandelanleihe-im-betrag-von-chf-200-millionen 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/endgueltige-zuteilung-von-basileas-wandelanleihe-im-betrag-von-chf-200-millionen 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/final-allocations-of-basilea-chf-200-million-senior-convertible-bonds 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-status-update-zu-klinischen-programmen 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-provides-clinical-program-updates 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basileas-head-of-global-human-resources-heidi-mc-daid-to-retire-and-ursula-eberhardt-named-as-successor 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basileas-head-of-global-human-resources-heidi-mc-daid-wird-in-den-ruhestand-treten-ursula-eberhardt-als-nachfolgerin-benannt 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/gsk-informiert-basilea-ueber-entscheidung-sein-us-alitretinoin-programm-nicht-fortzufuehren 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/gsk-informs-basilea-that-it-has-elected-not-to-continue-its-us-alitretinoin-program 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-solide-ergebnisse-des-geschaeftsjahrs-2015-bekannt-und-lanciert-mit-cresembar-ihr-zweites-spital-antiinfektivum-in-europa 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-solid-2015-full-year-results-and-is-launching-cresembar-its-second-hospital-anti-infective-in-europe 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-launching-antifungal-cresembar-isavuconazole-in-the-united-kingdom 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-lanciert-antimykotikum-cresembar-isavuconazol-im-vereinigten-koenigreich 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-launching-antifungal-cresembar-isavuconazole-in-germany 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-lanciert-antimykotikum-cresembar-isavuconazol-in-deutschland 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-that-the-lancet-infectious-diseases-published-results-from-the-cresembar-isavuconazole-open-label-study-for-the-treatment-of-mucormycosis 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-publikation-von-ergebnissen-aus-open-label-studie-mit-cresembar-isavuconazol-zur-behandlung-von-mukormykose-in-the-lancet-infectious-diseases 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-issues-agenda-for-annual-general-meeting-of-shareholders 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-veroeffentlicht-traktanden-fuer-ordentliche-generalversammlung 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-von-daten-zu-isavuconazol-und-ceftobiprol-auf-europaeischem-kongress-fuer-klinische-mikrobiologie-und-infektionskrankheiten-eccmid 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-isavuconazole-and-ceftobiprole-data-at-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-awarded-contract-by-barda-of-up-to-usd-100-million-funding-for-ceftobiprole-phase-3-program 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-vertrag-mit-barda-in-hoehe-von-bis-zu-usd-100-mio-fuer-phase-3-entwicklungsprogramm-von-ceftobiprol-ab 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-von-daten-zu-den-klinischen-onkologie-kandidaten-bal101553-und-bal3833-auf-aacr-tagung 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-data-on-clinical-oncology-programs-bal101553-and-bal3833-at-aacr-meeting 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-resolutions-proposed-by-the-board-of-directors-at-the-ordinary-general-meeting-of-shareholders-1 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-ordentlicher-generalversammlung-alle-antraege-des-verwaltungsrats-2 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-von-daten-zu-den-klinischen-onkologie-programmen-bal101553-und-bal3833-auf-asco-konferenz 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-data-on-clinical-oncology-programs-bal101553-and-bal3833-at-asco-meeting 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basileas-antifungal-cresembar-isavuconazole-launched-in-italy 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basileas-antimykotikum-cresembar-isavuconazol-in-italien-lanciert 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-halbjahresergebnisse-2016-cresembar-in-wichtigen-europaeischen-maerkten-eingefuehrt 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-2016-half-year-results-cresembar-launched-in-key-european-markets 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-distribution-agreement-with-hikma-for-cresembar-isavuconazole-in-the-mena-region 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vertriebsvereinbarung-mit-hikma-fuer-cresembar-isavuconazol-im-nahen-osten-und-nordafrika-bekannt 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-starts-continuous-infusion-phase-1-2a-clinical-study-with-oncology-drug-candidate-bal101553 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-startet-klinische-phase-1-2a-studie-mit-kontinuierlicher-infusion-des-onkologie-medikamentenkandidaten-bal101553 2019-01-04T15:36:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-liefer-vertriebs-und-lizenzvereinbarung-mit-grupo-biotoscana-fuer-cresembar-isavuconazol-und-zevterar-ceftobiprol-in-lateinamerika-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-supply-distribution-and-license-agreement-with-grupo-biotoscana-for-cresembar-isavuconazole-and-zevterar-ceftobiprole-in-latin-america 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-partnership-for-antifungal-isavuconazole-in-japan-with-asahi-kasei-pharma 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-partnerschaft-mit-asahi-kasei-pharma-fuer-antimykotikum-isavuconazol-in-japan-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vertriebsvereinbarung-mit-unimedic-fuer-cresembar-isavuconazol-und-zevterar-ceftobiprol-fuer-nordeuropa-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-distribution-agreement-with-unimedic-for-cresembar-isavuconazole-and-zevterar-ceftobiprole-in-the-nordic-countries 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basileas-antimykotikum-cresembar-isavuconazol-in-frankreich-lanciert 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basileas-antifungal-cresembar-isavuconazole-launched-in-france 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-erweitert-orale-klinische-phase-1-2a-studie-mit-onkologie-medikamentenkandidaten-bal101553-auf-glioblastom-patienten 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-expands-oncology-drug-candidate-bal101553-clinical-phase-1-2a-oral-study-to-include-glioblastoma-patients 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-names-new-member-of-its-extended-management-committee-1 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-ernennt-neues-mitglied-der-erweiterten-geschaeftsleitung 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-solide-ergebnisse-fuer-2016-und-erwartet-verdoppelung-der-produktverkaeufe-in-2017 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-solid-2016-results-and-expects-to-double-product-sales-in-2017 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-proposes-dr-nicole-onetto-as-new-member-of-the-board-of-directors 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-schlaegt-dr-nicole-onetto-als-neues-mitglied-des-verwaltungsrats-vor 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/auf-der-aacr-tagung-praesentierte-daten-zu-basileas-bal101553-zeigen-vielfaeltige-tumor-targeting-eigenschaften-sowie-kombinationspotential-mit-bevacizumab 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/data-presented-at-aacr-meeting-indicate-diverse-tumor-targeting-properties-of-basileas-bal101553-and-show-a-combination-potential-with-bevacizumab 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vereinbarung-mit-fda-ueber-special-protocol-assessments-fuer-klinische-phase-3-studien-mit-antibiotikum-ceftobiprol-bei-blutbahn-und-hautinfektionen-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-agreement-with-fda-on-special-protocol-assessments-for-antibiotic-ceftobiprole-phase-3-clinical-studies-in-bloodstream-and-skin-infections 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-ordentlicher-generalversammlung-alle-antraege-des-verwaltungsrats-1 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-resolutions-proposed-by-the-board-of-directors-at-the-ordinary-general-meeting-of-shareholders 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-neues-mitglied-fuer-die-erweiterte-geschaeftsleitung-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-names-new-member-of-its-extended-management-committee 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-praesentation-von-interim-daten-aus-klinischen-phase-1-2a-studien-mit-onkologie-medikamentenkandidaten-bal101553-auf-asco-tagung-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-presentation-of-interim-phase-1-2a-clinical-data-with-anticancer-drug-candidate-bal101553-at-asco-meeting 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-clinical-study-agreement-with-adult-brain-tumor-consortium-to-explore-bal101553-in-newly-diagnosed-glioblastoma 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-vereinbarung-mit-adult-brain-tumor-consortium-ueber-klinische-studie-zur-erprobung-von-bal101553-bei-neu-diagnostiziertem-glioblastom 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-zusaetzliche-usd-548-mio-von-barda-zur-finanzierung-des-phase-3-programms-von-ceftobiprol 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-awarded-usd-548-million-of-additional-funding-by-barda-to-support-phase-3-development-of-ceftobiprole 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-vertriebsvereinbarung-mit-avir-pharma-inc-fuer-cresembar-isavuconazol-und-zevterar-ceftobiprol-in-kanada 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-distribution-agreement-with-avir-pharma-inc-for-cresembar-isavuconazole-and-zevterar-ceftobiprole-in-canada 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-lizenzvereinbarung-mit-pfizer-ueber-antimykotikum-cresembar-isavuconazol-fuer-europa-russland-die-tuerkei-und-israel 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-license-agreement-with-pfizer-for-antifungal-cresembar-isavuconazole-for-europe-russia-turkey-and-israel 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-formellen-abschluss-der-lizenzvereinbarung-mit-pfizer-ueber-antimykotikum-cresembar-fuer-europa-russland-die-tuerkei-und-israel-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-completion-of-the-license-agreement-with-pfizer-for-antifungal-cresembar-for-europe-russia-turkey-and-israel 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-verbesserte-finanzergebnisse-fuer-das-erste-halbjahr-2017-aufgrund-gesteigerter-produktumsaetze-signifikante-fortschritte-bei-partnerschaften-und-in-entwicklungsprogrammen 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-improved-financial-results-in-half-year-2017-driven-by-growing-product-sales-significant-progress-on-partnering-and-development-programs 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-distribution-agreement-with-cardiome-to-commercialize-antibiotic-zevterar-mabelior-ceftobiprole-in-europe-and-israel 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vertriebsvereinbarung-mit-cardiome-zur-vermarktung-des-antibiotikums-zevterar-mabelior-ceftobiprol-in-europa-und-israel-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-lizenzvereinbarung-fuer-antibiotikum-zevterar-ceftobiprol-mit-shenzhen-china-resources-gosun-pharmaceutical-co-ltd-bekannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-license-agreement-for-antibiotic-zevterar-ceftobiprole-with-shenzhen-china-resources-gosun-pharmaceutical-co-ltd 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-erste-kommerzielle-meilensteinzahlung-aufgrund-starker-produktverkaeufe-von-cresembar-isavuconazol-in-den-usa 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-in-the-united-states-trigger-first-sales-milestone-payment-to-basilea 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basileas-chief-medical-officer-prof-achim-kaufhold-to-retire-and-dr-marc-engelhardt-named-as-successor 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basileas-chief-medical-officer-prof-achim-kaufhold-tritt-in-den-ruhestand-dr-marc-engelhardt-zum-nachfolger-ernannt 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-on-commercial-progress-of-antifungal-cresembar-in-europe 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-fortschritte-bei-der-kommerzialisierung-des-antimykotikums-cresembar-in-europa 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-extends-existing-license-agreement-with-pfizer-for-antifungal-cresembar-isavuconazole-to-china-and-asia-pacific 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-erweitert-bestehende-lizenzvereinbarung-mit-pfizer-ueber-antimykotikum-cresembar-isavuconazol-auf-china-und-den-asiatisch-pazifischen-raum 2019-01-04T15:29:45+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-that-ceftobiprole-received-qidp-designation-from-us-fda-for-the-treatment-of-staphylococcus-aureus-bacteremia-sab 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-ceftobiprol-von-der-us-arzneimittelbehoerde-fda-den-qidp-status-zur-behandlung-von-staphylococcus-aureus-bakteriaemie-sab-erhalten-hat 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-start-of-clinical-phase-1-study-in-collaboration-with-the-us-adult-brain-tumor-consortium-to-explore-bal101553-in-newly-diagnosed-glioblastoma 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-start-von-klinischer-phase-1-studie-in-zusammenarbeit-mit-dem-us-amerikanischen-adult-brain-tumor-consortium-zur-erprobung-von-bal101553-bei-neu-diagnostiziertem-glioblastom-bekannt 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-completion-of-the-license-agreement-extension-with-pfizer-for-antifungal-cresembar-for-china-and-asia-pacific 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-formellen-abschluss-der-lizenzvereinbarungs-erweiterung-mit-pfizer-ueber-antimykotikum-cresembar-fuer-china-und-den-asiatisch-pazifischen-raum-bekannt 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basileas-ceo-ronald-scott-will-retire-chief-commercial-officer-david-veitch-named-as-successor-changes-in-the-board-of-directors 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basileas-ceo-ronald-scott-wird-in-den-ruhestand-treten-chief-commercial-officer-david-veitch-zum-nachfolger-ernannt-veraenderungen-im-verwaltungsrat 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-clinical-phase-3-study-start-with-antibiotic-ceftobiprole-in-skin-infections-under-barda-contract 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-start-von-klinischer-phase-3-studie-mit-antibiotikum-ceftobiprol-bei-hautinfektionen-im-rahmen-des-barda-vertrags-bekannt 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-significantly-improved-financial-results-in-2017 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-meldet-signifikant-verbesserte-finanzergebnisse-im-jahr-2017 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-names-adesh-kaul-as-new-member-of-its-management-committee 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-ernennt-adesh-kaul-zum-neuen-mitglied-der-geschaeftsleitung 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-launch-of-antibiotic-zevtera-ceftobiprole-in-argentina-by-grupo-biotoscana 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-markteinfuehrung-des-antibiotikums-zevtera-ceftobiprol-in-argentinien-durch-grupo-biotoscana-bekannt 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-launch-of-antibiotic-zevtera-ceftobiprole-in-canada-by-avir-pharma 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-markteinfuehrung-des-antibiotikums-zevtera-ceftobiprol-in-kanada-durch-avir-pharma-bekannt 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-licenses-late-stage-oncology-drug-candidate-derazantinib-from-arqule 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-lizenzvereinbarung-mit-arqule-ueber-derazantinib-ab-einen-onkologie-medikamenten-kandidaten-in-der-fortgeschrittenen-klinischen-entwicklung 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-start-of-clinical-phase-3-study-in-japan-by-asahi-kasei-pharma-with-antifungal-isavuconazole 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-beginn-der-klinischen-phase-3-studie-mit-dem-antimykotikum-isavuconazol-in-japan-durch-asahi-kasei-pharma-bekannt 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting-of-shareholders 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-ordentlicher-generalversammlung-alle-antraege-des-verwaltungsrats 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentations-of-isavuconazole-and-ceftobiprole-data-at-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentationen-von-isavuconazol-und-ceftobiprol-daten-am-europaeischen-kongress-fuer-klinische-mikrobiologie-und-infektionskrankheiten-eccmid 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-appointment-of-chief-technology-officer-and-appointment-of-head-of-global-quality-management 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-ernennt-chief-technology-officer-sowie-head-of-global-quality-management 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-launch-of-antibiotic-zevtera-ceftobiprole-in-saudi-arabia-by-hikma-pharmaceuticals-llc 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-meldet-die-lancierung-des-antibiotikums-zevtera-ceftobiprol-in-saudi-arabien-durch-hikma-pharmaceuticals-llc 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-pharmaceutica-subscription-to-basileas-press-release-newsletter 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-pharmaceutica-abonnement-des-basilea-pressemitteilungs-newsletters 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-phase-1-clinical-data-with-anticancer-drug-candidate-bal101553-at-asco-meeting 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-von-klinischen-phase-1-daten-fuer-onkologie-medikamenten-kandidaten-bal101553-auf-asco-tagung 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-starts-clinical-phase-2a-expansion-with-bal101553-in-ovarian-cancer-and-glioblastoma 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-beginnt-phase-2a-erweiterungsstudie-zur-klinischen-erprobung-von-bal101553-bei-eierstockkrebs-und-glioblastom 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-receipt-of-milestone-payment-based-on-first-cresembar-approval-in-latin-america 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-erhalt-einer-meilensteinzahlung-aufgrund-der-ersten-cresembar-zulassung-in-lateinamerika-bekannt 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-starts-clinical-phase-3-study-with-antibiotic-ceftobiprole-in-staphylococcus-aureus-bacteremia-sab 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-startet-klinische-phase-3-studie-mit-antibiotikum-ceftobiprol-bei-staphylococcus-aureus-bakteriaemie-sab 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-on-first-cresembar-approval-in-mena-region 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-erste-cresembar-zulassung-in-der-mena-region 2019-01-04T15:35:30+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-half-year-financial-results-reflecting-strong-in-market-product-sales-growth-in-addition-to-progress-and-expansion-of-the-rd-pipeline 2019-01-08T10:39:19+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-halbjahresergebnisse-bekannt-gepraegt-von-starkem-wachstum-der-in-market-sales-ihrer-produkte-sowie-vom-fortschritt-und-der-erweiterung-ihrer-fe-pipeline 2019-01-08T10:39:19+01:00 0.5 https://www.basilea.com/news/news/basilea-presents-preclinical-data-on-its-anticancer-drug-candidate-bal101553-at-eortc-nci-aacr-symposium 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-praeklinische-daten-zu-ihrem-onkologischen-medikamentenkandidaten-bal101553-auf-eortc-nci-aacr-symposium 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/basilea-pharmaceutica-ag-continued-strong-cresembar-isavuconazole-us-sales-performance-triggers-chf-10-million-milestone-payment-to-basilea 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/anhaltend-starke-umsatzentwicklung-von-cresembar-isavuconazol-in-den-usa-loest-chf-10-mio-meilensteinzahlung-an-basilea-aus 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/basilea-presenting-at-the-37th-annual-j-p-morgan-healthcare-conference-delivering-on-its-strategy 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentation-auf-der-37-j-p-morgan-healthcare-conference-umsetzung-der-strategie 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-higher-than-expected-preliminary-revenue-of-chf-133-million-for-financial-year-2018 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/basilea-weist-einen-hohen-ueber-den-erwartungen-liegenden-vorlaeufigen-umsatz-von-chf-133-mio-fuer-das-geschaeftsjahr-2018-aus 2019-01-18T16:25:53+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-positive-interim-results-from-registrational-phase-2-study-with-oncology-drug-candidate-derazantinib-in-intrahepatic-cholangiocarcinoma-icca 2019-05-02T11:18:13+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-positive-interim-ergebnisse-aus-phase-2-registrierungsstudie-mit-dem-krebsmedikamenten-kandidaten-derazantinib-bei-intrahepatischem-cholangiokarzinom-icca-bekannt 2019-05-02T11:18:13+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-collaboration-to-study-derazantinib-and-atezolizumab-tecentriqr-in-urothelial-cancer 2019-05-02T11:18:13+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-kooperation-zur-klinischen-erprobung-von-derazantinib-und-atezolizumab-tecentriqr-bei-urothelkarzinom-blasenkrebs-bekannt 2019-05-02T11:18:13+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-change-in-the-management-committee-adesh-kaul-appointed-cfo 2019-05-02T11:18:13+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-wechsel-in-der-geschaeftsleitung-bekannt-adesh-kaul-zum-cfo-ernannt 2019-05-02T11:18:13+02:00 0.5 https://www.basilea.com/news/news/strong-european-cresembar-isavuconazole-sales-trigger-usd-5-million-milestone-payment-to-basilea-from-pfizer 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/starke-cresembar-isavuconazol-verkaeufe-in-europa-loesen-usd-5-mio-meilensteinzahlung-von-pfizer-an-basilea-aus 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-revenue-growth-and-significant-pipeline-progress-for-full-year-2018 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/basilea-verzeichnet-starkes-umsatzwachstum-und-signifikante-pipeline-fortschritte-fuer-das-gesamtjahr-2018 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-der-generalversammlung-alle-antraege-des-verwaltungsrats 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-isavuconazole-cresembar-and-ceftobiprole-zevterar-presentations-at-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentationen-zu-isavuconazol-cresembar-und-ceftobiprol-zevterar-auf-dem-europaeischen-kongress-fuer-klinische-mikrobiologie-und-infektionskrankheiten-eccmid 2019-05-02T10:59:05+02:00 0.5 https://www.basilea.com/news/news/basileas-partner-avir-pharma-has-launched-antifungal-cresembar-isavuconazole-in-canada-1 2019-05-05T07:15:01+02:00 0.5 https://www.basilea.com/news/news/basileas-partner-avir-pharma-lanciert-antimykotikum-cresembar-isavuconazol-in-kanada-1 2019-05-02T11:14:55+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-publication-of-clinical-data-for-anticancer-drug-candidates-bal101553-in-glioblastoma-and-derazantinib-in-intrahepatic-cholangiocarcinoma-at-asco-meeting 2019-06-04T07:15:02+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-veroeffentlichung-klinischer-daten-zu-den-krebsmedikamenten-kandidaten-bal101553-fuer-glioblastome-und-derazantinib-fuer-intrahepatische-cholangiokarzinome-auf-der-asco-tagung 2019-06-04T07:15:02+02:00 0.5 https://www.basilea.com/news/news/basilea-extends-phase-2-study-with-derazantinib-in-intrahepatic-bile-duct-cancer-icca-to-include-patients-with-fgfr2-gene-mutations-or-amplifications 2019-07-02T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-erweitert-phase-2-studie-mit-derazantinib-beim-intrahepatischen-gallengangskarzinom-icca-um-studienkohorte-fuer-patienten-mit-mutation-oder-amplifikation-des-fgfr2-gens 2019-07-02T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-positive-results-of-phase-3-target-study-with-antibiotic-ceftobiprole-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-absssi 2019-08-06T07:25:02+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-positive-ergebnisse-der-phase-3-studie-target-mit-dem-antibiotikum-ceftobiprol-zur-behandlung-akuter-bakterieller-haut-und-weichteilinfektionen-absssi-bekannt 2019-08-06T07:25:02+02:00 0.5 https://www.basilea.com/news/news/basilea-starts-phase-1-2-study-with-derazantinib-in-urothelial-cancer 2019-08-13T07:25:01+02:00 0.5 https://www.basilea.com/news/news/basilea-startet-phase-1-2-studie-mit-derazantinib-in-patienten-mit-urothelkarzinom 2019-08-13T07:25:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-significantly-increased-cash-generating-revenue-flat-operating-expenses-and-reduced-net-loss-for-half-year-2019 2019-08-20T07:25:01+02:00 0.5 https://www.basilea.com/news/news/basilea-zeigt-zum-halbjahr-2019-eine-signifikante-zunahme-von-cash-generierenden-umsaetzen-einen-konstant-gebliebenen-betriebsaufwand-und-einen-verringerten-konzernverlust 2019-08-20T07:25:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-completion-of-patient-enrolment-in-phase-1-study-with-oral-bal101553-in-brain-cancer 2019-08-28T07:25:02+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-abschluss-der-patientenrekrutierung-fuer-phase-1-studie-mit-oralem-bal101553-bei-hirntumoren-bekannt 2019-08-28T07:25:02+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-at-esmo-meeting-that-drug-candidate-derazantinib-showed-clinical-benefit-in-intrahepatic-cholangiocarcinoma-icca-patients-with-various-fgfr2-genetic-aberrations 2019-09-30T07:25:01+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-auf-esmo-meeting-ueber-klinischen-nutzen-des-medikamentenkandidaten-derazantinib-bei-patienten-mit-intrahepatischem-cholangio-karzinom-icca-und-verschiedenen-fgfr2-genaberrationen 2019-09-30T07:25:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-marketing-authorization-of-antifungal-cresembar-in-brazil 2019-10-29T07:25:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-marktzulassung-von-antimykotikum-cresembar-in-brasilien-bekannt 2019-10-29T07:25:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-positive-preclinical-data-on-oncology-drug-candidates-derazantinib-and-lisavanbulin-at-aacr-nci-eortc-conference 2019-10-31T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-positive-praeklinische-daten-zu-onkologischen-medikamentenkandidaten-derazantinib-und-lisavanbulin-auf-aacr-nci-eortc-konferenz 2019-10-31T07:20:01+01:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-trigger-second-sales-milestone-this-year-from-pfizer-to-basilea-of-usd-7-million 2019-12-06T07:21:25+01:00 0.5 https://www.basilea.com/news/news/anhaltend-starke-cresembar-isavuconazol-umsaetze-loesen-den-zweiten-umsatzmeilenstein-von-pfizer-an-basilea-in-diesem-jahr-in-hoehe-von-usd-7-mio-aus 2019-12-06T07:21:25+01:00 0.5 https://www.basilea.com/news/news/basilea-plans-progression-of-oncology-candidate-lisavanbulin-to-targeted-biomarker-driven-phase-2-study 2019-12-17T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-treibt-die-entwicklung-ihres-krebsmedikamentenkandidaten-lisavanbulin-in-richtung-gezielte-therapie-voran-und-plant-biomarker-basierte-phase-2-studie 2019-12-17T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-at-the-38th-annual-j-p-morgan-healthcare-conference-significant-progress-in-cresemba-commercialization-and-rd-portfolio-in-2019 2020-01-09T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-an-der-38-j-p-morgan-healthcare-conference-in-2019-signifikante-fortschritte-bei-der-kommerzialisierung-von-cresemba-und-im-fe-portfolio 2020-01-09T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-total-revenue-exceeding-guidance-driven-by-higher-than-expected-contributions-from-cresembar-and-zevterar-in-2019 2020-01-11T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-weist-fuer-2019-einen-ueber-der-guidance-liegenden-gesamtumsatz-aus-getrieben-durch-einen-hoeher-als-erwarteten-umsatzbeitrag-von-cresembar-und-zevterar 2020-06-23T20:33:32+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-clinical-supply-agreement-for-its-planned-study-fides-03-with-derazantinib-in-gastric-cancer 2020-01-23T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-clinical-supply-agreement-fuer-geplante-fides-03-studie-mit-derazantinib-bei-magenkrebs-bekannt 2020-01-23T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-activity-of-derazantinib-in-preclinical-models-of-gastric-cancer-at-asco-gastrointestinal-cancers-symposium 2020-01-24T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-auf-asco-gastrointestinal-cancers-symposium-ueber-aktivitaet-von-derazantinib-in-praeklinischen-magenkrebs-modellen 2020-01-24T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-significant-revenue-growth-from-marketed-products-and-pipeline-progress-for-full-year-2019 2020-02-19T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-fuer-das-gesamtjahr-2019-signifikantes-umsatzwachstum-aus-vermarkteten-produkten-und-fortschritte-in-ihrer-pipeline 2020-02-19T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-the-launch-of-antifungal-cresembar-isavuconazole-in-australia-triggering-the-first-milestone-payment-related-to-asia-pacific 2020-02-28T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-markteinfuehrung-des-antimykotikums-cresembar-isavuconazol-in-australien-bekannt-was-erste-meilensteinzahlung-fuer-den-asiatisch-pazifischen-raum-ausloest 2020-03-07T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting-2 2020-04-09T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-der-generalversammlung-alle-antraege-des-verwaltungsrats-2 2020-04-09T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-appointment-of-new-head-of-global-quality-management 2020-04-30T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-ernennung-einer-neuen-leiterin-fuer-das-globale-qualitaetsmanagement-bekannt 2020-04-30T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-provides-corporate-update 2020-05-29T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-unternehmens-update 2020-05-29T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-receives-chf-5-million-milestone-payment-related-to-marketing-authorization-of-antifungal-cresembar-in-russia 2020-06-24T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-chf-5-mio-meilensteinzahlung-im-zusammenhang-mit-der-marktzulassung-des-antimykotikums-cresembar-in-russland 2020-06-23T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-enters-into-sale-and-leaseback-agreement-for-corporate-headquarters-building 2020-06-24T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-sale-and-lease-back-vereinbarung-fuer-das-gebaeude-der-konzernzentrale-ab 2020-06-24T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-launches-the-placement-of-chf-100-million-senior-convertible-bonds-with-an-increase-option-of-chf-25-million 2020-06-24T20:42:52+02:00 0.5 https://www.basilea.com/news/news/basilea-lanciert-die-platzierung-einer-vorrangigen-wandelanleihe-von-chf-100-millionen-mit-einer-erhoehungsoption-von-chf-25-millionen 2020-06-24T20:42:52+02:00 0.5 https://www.basilea.com/news/news/basilea-successfully-places-chf-125-million-senior-convertible-bonds 2020-06-25T07:02:11+02:00 0.5 https://www.basilea.com/news/news/basilea-platziert-erfolgreich-vorrangige-wandelanleihen-im-umfang-von-chf-125-millionen 2020-06-25T07:02:11+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-partial-repurchase-offer-for-at-least-chf-90-million-and-up-to-chf-110-million-in-principal-amount-of-its-outstanding-convertible-bonds-due-2022 2020-06-25T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-kuendigt-teilweises-rueckkaufangebot-ueber-mindestens-chf-90-millionen-und-bis-zu-chf-110-millionen-nennwert-ihrer-ausstehenden-wandelanleihen-mit-faelligkeit-2022-an 2020-06-25T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-move-of-corporate-headquarters-to-allschwil-canton-of-basel-landschaft-in-2022 2020-06-30T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-den-umzug-des-firmensitzes-nach-allschwil-kanton-basel-landschaft-fuer-das-jahr-2022-bekannt 2020-06-30T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-the-start-of-the-offer-period-of-its-partial-repurchase-offer-for-its-outstanding-convertible-bonds-due-2022 2020-07-10T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-den-beginn-der-angebotsfrist-ihres-teilrueckkaufsangebots-fuer-ihre-ausstehenden-wandelanleihen-mit-faelligkeit-2022-bekannt 2020-07-10T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-the-launch-of-antifungal-cresembar-isavuconazole-in-taiwan-triggering-the-second-milestone-payment-related-to-asia-pacific 2020-07-16T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-markteinfuehrung-des-antimykotikums-cresembar-isavuconazol-in-taiwan-bekannt-wodurch-die-zweite-meilensteinzahlung-fuer-den-asiatisch-pazifischen-raum-ausgeloest-wird 2020-07-16T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-bonds-tendered-in-an-aggregate-principal-amount-of-approximately-chf-47-million 2020-07-17T07:20:02+02:00 0.5 https://www.basilea.com/news/news/obligationen-der-basilea-mit-einem-gesamtnennbetrag-von-ungefaehr-chf-47-millionen-angedient 2020-07-17T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-continues-with-the-implementation-of-the-repurchase-offer-and-the-issuance-of-new-bonds 2020-07-17T19:15:21+02:00 0.5 https://www.basilea.com/news/news/basilea-fuehrt-das-rueckkaufangebot-und-die-ausgabe-neuer-anleihen-fort 2020-07-17T19:15:21+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-completion-of-patient-enrolment-into-first-cohort-of-phase-2-study-fides-01-with-derazantinib-in-bile-duct-cancer-icca 2020-07-20T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-abschluss-der-patientenrekrutierung-fuer-die-erste-kohorte-der-phase-2-studie-fides-01-mit-derazantinib-bei-gallengangkrebs-icca-bekannt 2020-07-20T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-a-conversion-price-of-chf-6250-for-its-new-bonds-and-the-acceptance-of-tendered-bonds-in-an-aggregated-principal-amount-of-approximately-chf-47-million 2020-07-21T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-einen-wandelpreis-von-chf-6250-fuer-ihre-neue-anleihe-und-die-annahme-angedienter-wandelobligationen-mit-einem-gesamtnennbetrag-von-rund-chf-47-millionen-bekannt 2020-07-21T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-data-presentations-at-esmo-virtual-congress-2020 2020-07-28T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-kuendigt-praesentation-von-daten-auf-dem-esmo-virtual-congress-2020-an 2020-07-28T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-completion-of-its-transaction-involving-a-partial-repurchase-of-its-existing-bond-and-the-issuance-of-a-new-bond 2020-07-29T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-den-abschluss-ihrer-transaktion-mit-einem-teilweisen-rueckkauf-ihrer-bestehenden-anleihe-und-der-ausgabe-einer-neuen-anleihe-bekannt 2020-07-29T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-acceptance-for-regulatory-review-of-pfizers-marketing-authorization-application-for-antifungal-isavuconazole-cresembar-in-china 2020-08-08T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-pfizers-antrag-auf-marktzulassung-in-china-fuer-das-antimykotikum-isavuconazol-cresembar-zur-regulatorischen-pruefung-angenommen-wurde 2020-08-08T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-financial-results-for-half-year-2020-progress-in-rd-portfolio-and-successful-completion-of-strategic-projects-despite-covid-19 2020-08-11T07:20:04+02:00 0.5 https://www.basilea.com/news/news/basilea-meldet-starke-finanzergebnisse-fuer-das-erste-halbjahr-2020-fortschritte-im-fe-portfolio-und-erfolgreichen-abschluss-strategischer-projekte-trotz-covid-19 2020-08-11T07:20:04+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-data-from-poster-presentations-at-esmo-virtual-congress-2020 2020-09-22T07:18:15+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-daten-von-poster-praesentationen-am-esmo-virtual-congress-2020 2020-09-22T07:18:15+02:00 0.5 https://www.basilea.com/news/news/basilea-starts-phase-1-2-study-fides-03-with-derazantinib-in-patients-with-gastric-cancer 2020-09-28T07:17:38+02:00 0.5 https://www.basilea.com/news/news/basilea-beginnt-phase-1-2-studie-fides-03-mit-derazantinib-bei-patienten-mit-magenkrebs 2020-09-28T07:17:38+02:00 0.5 https://www.basilea.com/news/news/basilea-initiates-targeted-biomarker-driven-phase-2-study-with-lisavanbulin-in-patients-with-brain-cancer 2020-09-29T07:20:03+02:00 0.5 https://www.basilea.com/news/news/basilea-initiiert-zielgerichtete-biomarker-basierte-phase-2-studie-mit-lisavanbulin-bei-patienten-mit-hirntumoren 2020-09-29T07:20:03+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-pooled-efficacy-data-for-derazantinib-in-icca-patients-with-fgfr2-gene-mutations-and-amplifications-presented-at-esmo-map-virtual-congress-2020 2020-10-13T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-gepoolter-wirksamkeitsdaten-fuer-derazantinib-bei-icca-patienten-mit-mutationen-und-amplifikationen-der-fgfr2-gene-auf-dem-esmo-map-virtual-congress-2020 2020-10-13T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-interim-results-from-phase-1-2-study-fides-02-exploring-derazantinib-in-patients-with-advanced-urothelial-cancer 2020-10-14T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-interim-ergebnisse-aus-phase-1-2-studie-fides-02-in-der-derazantinib-bei-patienten-mit-fortgeschrittenem-urothelkarzinom-erprobt-wird 2020-10-14T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-presents-preclinical-data-on-anti-angiogenic-activity-of-derazantinib-at-ena-2020 2020-10-27T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-praeklinische-daten-zur-anti-angiogenen-aktivitaet-von-derazantinib-auf-der-ena-2020 2020-10-27T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-clinical-trial-collaboration-and-supply-agreement-with-eli-lilly-and-company-for-ramucirumab-in-the-ongoing-fides-03-study-with-derazantinib-in-gastric-cancer 2020-10-29T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-clinical-trial-collaboration-and-supply-agreement-mit-eli-lilly-and-company-fuer-ramucirumab-fuer-die-laufende-fides-03-studie-mit-derazantinib-bei-magenkrebs-bekannt 2020-10-29T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-approval-of-antibiotic-zevterar-in-china-to-treat-community-acquired-pneumonia-and-hospital-acquired-pneumonia 2020-11-07T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-zulassung-von-antibiotikum-zevterar-in-china-zur-behandlung-von-ambulant-und-im-spital-erworbener-lungenentzuendung-bekannt 2020-11-07T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-acceptance-for-regulatory-review-of-pfizers-marketing-authorization-application-for-antifungal-isavuconazole-cresembar-in-invasive-aspergillosis-in-china 2020-11-26T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-annahme-von-pfizers-antrag-auf-marktzulassung-des-antimykotikums-isavuconazol-cresembar-bei-invasiver-aspergillose-zur-regulatorischen-pruefung-in-china-bekannt 2020-11-26T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basileas-partner-asahi-kasei-pharma-completes-patient-enrolment-in-phase-3-study-with-antifungal-isavuconazole-cresembar-in-japan 2021-01-08T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basileas-partner-asahi-kasei-pharma-schliesst-patientenrekrutierung-in-phase-3-studie-mit-antimykotikum-isavuconazol-cresembar-in-japan-ab 2021-01-08T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-preliminary-2020-revenue-and-portfolio-progress 2021-01-12T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vorlaeufige-umsatzzahlen-fuer-2020-bekannt-und-berichtet-ueber-fortschritte-im-portfolio 2021-01-12T07:20:02+01:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-trigger-milestone-from-pfizer-to-basilea-of-usd-10-million 2021-02-10T07:20:01+01:00 0.5 https://www.basilea.com/news/news/anhaltend-starke-cresembar-isavuconazol-umsaetze-loesen-usd-10-mio-meilensteinzahlung-von-pfizer-an-basilea-aus 2021-02-10T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-positive-topline-results-from-phase-2-study-fides-01-for-derazantinib-in-fgfr2-gene-fusion-positive-patients-with-bile-duct-cancer-icca 2021-02-11T07:19:06+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-positive-topline-ergebnisse-aus-phase-2-studie-fides-01-mit-derazantinib-bei-patienten-mit-gallengangkrebs-icca-und-fusionen-des-fgfr2-gens-bekannt 2021-02-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-achieves-preclinical-milestone-in-oncology-collaboration-on-potential-first-in-class-kinase-inhibitor 2021-02-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-erreicht-praeklinischen-meilenstein-im-rahmen-einer-kooperation-zur-entwicklung-eines-potenziellen-first-in-class-kinase-inhibitors-fuer-die-krebstherapie 2021-02-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-derazantinib-pd-l1-checkpoint-inhibitor-combination-results-from-dose-finding-part-of-fides-02-study-in-patients-with-solid-tumors-at-asco-gu-symposium 2021-02-13T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-auf-asco-gu-symposium-dosisfindungs-ergebnisse-fuer-derazantinib-pd-l1-checkpoint-inhibitor-kombination-aus-fides-02-studie-fuer-patienten-mit-soliden-tumoren 2021-02-13T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-divestment-of-its-chinese-rd-subsidiary-to-pht-international 2021-02-16T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-kuendigt-veraeusserung-ihres-chinesischen-fe-tochterunternehmens-an-pht-international-an 2021-02-16T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-2020-financial-results-and-significant-progress-in-the-clinical-pipeline-of-its-oncology-assets 2021-02-17T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-meldet-fuer-2020-starke-finanzergebnisse-und-deutliche-fortschritte-in-ihrer-klinischen-onkologie-pipeline 2021-02-17T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-launches-a-private-placement-of-new-shares-by-way-of-an-accelerated-bookbuilding 2021-02-24T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-lanciert-eine-privatplatzierung-von-neuen-aktien-mittels-accelerated-bookbuilding-verfahren 2021-02-24T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-successfully-placed-1-million-new-registered-shares-raising-gross-proceeds-of-chf-4575-million 2021-02-25T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-platziert-erfolgreich-1-million-neue-namenaktien-und-erzielt-dabei-einen-bruttoerloes-von-chf-4575-millionen 2021-02-25T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-positive-interim-results-from-phase-2-study-fides-01-for-derazantinib-in-fgfr2-gene-mutation-or-amplification-positive-patients-with-bile-duct-cancer-icca 2021-03-27T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-positive-interim-ergebnisse-fuer-phase-2-studie-fides-01-mit-derazantinib-bei-patienten-mit-gallengangkrebs-icca-mit-mutationen-oder-amplifikationen-des-fgfr2-gens 2021-03-27T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-closing-of-previously-announced-transaction-regarding-divestment-of-its-chinese-rd-subsidiary 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-abschluss-der-zuvor-angekuendigten-transaktion-zur-veraeusserung-ihres-chinesischen-fe-tochterunternehmens-bekannt 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting-1 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-der-generalversammlung-alle-antraege-des-verwaltungsrats-1 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-awarded-carb-x-grant-of-up-to-usd-27-million-to-develop-novel-class-antibiotic 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-von-carb-x-foerderung-von-bis-zu-usd-27-mio-fuer-die-entwicklung-eines-antibiotikums-aus-einer-neuen-wirkstoffklasse 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-provides-updates-on-efficacy-data-with-derazantinib-in-bile-duct-cancer-and-on-ongoing-clinical-programs-in-urothelial-and-gastric-cancer 2021-07-10T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-aktualisierte-daten-zur-wirksamkeit-von-derazantinib-bei-gallengangkrebs-bekannt-und-informiert-ueber-laufende-klinische-programme-in-blasen-und-magenkrebs 2021-11-03T12:22:39+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-new-prevalence-data-for-eb1-a-potential-response-predictive-biomarker-for-lisavanbulin-in-glioblastoma-and-other-tumor-types-at-asco-annual-meeting 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-auf-der-asco-jahrestagung-neue-praevalenzdaten-fuer-eb1-einen-potenziellen-biomarker-fuer-das-ansprechen-auf-die-behandlung-mit-lisavanbulin-bei-glioblastom-und-anderen-tumortypen 2021-07-01T13:49:26+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-distribution-agreement-with-jsc-lancet-for-antibiotic-zevterar-ceftobiprole-covering-russia-and-the-eurasian-economic-union 2021-07-14T19:18:45+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vertriebsvereinbarung-mit-jsc-lancet-fuer-antibiotikum-zevterar-ceftobiprol-fuer-russland-und-die-eurasische-wirtschaftsunion-bekannt 2021-07-14T19:18:45+02:00 0.5 https://www.basilea.com/news/news/basileas-partner-asahi-kasei-pharma-prepares-nda-filing-for-the-marketing-authorization-of-isavuconazole-in-japan-based-on-positive-phase-3-study-results 2021-07-26T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basierend-auf-positiven-phase-3-ergebnissen-bereitet-basileas-partner-asahi-kasei-pharma-die-einreichung-eines-antrags-auf-marktzulassung-nda-von-isavuconazol-in-japan-vor 2021-07-26T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-us-fda-orphan-drug-designation-granted-to-lisavanbulin-for-the-treatment-of-malignant-glioma 2021-07-30T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-erhalt-des-orphan-drug-status-von-der-us-amerikanischen-fda-fuer-lisavanbulin-fuer-die-behandlung-von-malignen-gliomen-bekannt 2021-07-30T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-awarded-additional-usd-43-million-by-barda-to-support-phase-3-development-of-ceftobiprole 2021-11-15T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-von-barda-zusaetzliche-usd-43-mio-zur-unterstuetzung-des-phase-3-entwicklungsprogramms-von-ceftobiprol 2021-11-15T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-financial-results-for-half-year-2021-with-significantly-increased-cash-flow-from-marketed-brands-and-increases-2021-full-year-guidance 2021-12-07T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-meldet-starke-finanzergebnisse-fuer-das-erste-halbjahr-2021-mit-deutlich-erhoehtem-cashflow-durch-vermarktete-produkte-und-erhoeht-finanziellen-ausblick-fuer-gesamtjahr-2021 2021-12-07T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-presents-full-safety-and-efficacy-data-set-on-derazantinib-in-patients-with-fgfr2-fusion-positive-icca-at-esmo-congress 2021-12-16T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-auf-esmo-kongress-vollstaendige-daten-zur-sicherheit-und-wirksamkeit-von-derazantinib-bei-patienten-mit-fgfr2-fusions-positivem-icca 2021-12-16T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basileas-partner-asahi-kasei-pharma-filed-new-drug-application-for-the-marketing-authorization-of-isavuconazole-in-japan 2021-12-20T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basileas-partner-asahi-kasei-pharma-reicht-antrag-auf-marktzulassung-nda-von-isavuconazol-in-japan-ein 2021-12-20T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-presents-preclinical-data-on-synergy-between-derazantinib-and-paclitaxel-in-gastric-tumor-models-at-ane-conference 2022-01-05T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-auf-ane-konferenz-praeklinische-daten-zur-synergie-von-derazantinib-und-paclitaxel-in-tumormodellen-fuer-magenkrebs 2022-01-05T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-submission-of-investigational-new-drug-application-for-novel-oncology-drug-candidate-bal0891 2022-01-06T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-einreichung-eines-investigational-new-drug-antrags-fuer-medikamentenkandidaten-bal0891-zur-krebsbehandlung-bekannt 2022-01-06T07:20:01+01:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-by-pfizer-trigger-usd-10-million-sales-milestone-payment-to-basilea 2022-01-09T07:20:01+01:00 0.5 https://www.basilea.com/news/news/anhaltend-starke-cresembar-isavuconazol-umsaetze-von-pfizer-loesen-usd-10-mio-meilensteinzahlung-an-basilea-aus 2022-01-09T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-fda-approval-of-investigational-new-drug-application-for-novel-oncology-drug-candidate-bal0891 2022-01-10T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-fda-genehmigung-des-investigational-new-drug-antrags-fuer-medikamentenkandidaten-bal0891-zur-krebsbehandlung-bekannt 2022-01-10T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-receives-usd-10-million-milestone-payment-related-to-approval-of-antifungal-cresembar-isavuconazole-in-china 2022-01-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-usd-10-mio-meilensteinzahlung-aufgrund-von-marktzulassung-des-antimykotikums-cresembar-isavuconazol-in-china 2022-01-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-on-portfolio-progress-made-in-2021 2022-01-23T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-die-im-jahr-2021-erzielten-fortschritte-im-portfolio 2022-01-23T07:20:01+01:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-by-astellas-in-the-us-trigger-chf-15-million-sales-milestone-payment-to-basilea 2022-02-14T07:20:01+01:00 0.5 https://www.basilea.com/news/news/starke-cresembar-isavuconazol-umsaetze-von-astellas-in-den-usa-loesen-chf-15-mio-meilensteinzahlung-an-basilea-aus 2022-02-14T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-exceeds-2021-financial-guidance-on-preliminary-revenue-and-year-end-cash-position 2022-03-07T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-uebertrifft-bei-vorlaeufigen-umsatzzahlen-und-der-cash-position-zum-jahresende-die-prognosen-fuer-2021 2022-03-07T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-completion-of-patient-enrolment-in-phase-3-eradicate-study-investigating-ceftobiprole-in-bloodstream-infections 2022-04-12T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-abschluss-der-patientenrekrutierung-fuer-phase-3-studie-eradicate-mit-ceftobiprol-bei-blutbahninfektionen-bekannt 2022-04-12T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-approval-of-antifungal-cresembar-isavuconazole-for-invasive-aspergillosis-in-china 2022-04-13T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-marktzulassung-des-antimykotikums-cresembar-isavuconazol-fuer-invasive-aspergillose-in-china-bekannt 2022-04-13T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-updated-interim-results-for-icca-patients-with-fgfr2-mutations-and-amplifications-from-phase-2-study-fides-01-at-asco-gi-cancers-symposium 2022-04-26T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-auf-asco-gi-cancers-symposium-aktualisierte-interim-ergebnisse-fuer-patienten-mit-icca-und-fgfr2-mutationen-und-amplifikationen-aus-kohorte-2-der-phase-2-studie-fides-01 2022-04-26T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-to-become-a-leading-anti-infectives-company-backed-by-strong-financial-results-2021 2022-06-16T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-auf-dem-weg-zu-einem-fuehrenden-antiinfektiva-unternehmen-unterstuetzt-durch-starke-finanzergebnisse-2021 2022-06-16T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-preclinical-data-on-anti-cancer-activity-of-novel-oncology-drug-candidate-bal0891-at-esmo-tat-congress 2022-06-23T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-auf-esmo-tat-kongress-praeklinische-daten-zur-anti-krebs-aktivitaet-ihres-neuartigen-krebsmedikamentenkandidaten-bal0891 2022-06-23T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-preclinical-data-on-oncology-drug-candidates-bal0891-derazantinib-and-lisavanbulin-at-aacr-annual-meeting 2022-06-26T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praeklinische-daten-zu-onkologiekandidaten-bal0891-derazantinib-und-lisavanbulin-auf-der-aacr-jahrestagung 2022-06-26T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting-3 2022-06-27T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-der-generalversammlung-alle-antraege-des-verwaltungsrats-3 2022-06-27T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-licensing-of-a-novel-first-in-class-antifungal-program-from-fox-chase-chemical-diversity-center 2022-07-11T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-die-lizenzierung-eines-neuartigen-first-in-class-antipilz-programms-von-fox-chase-chemical-diversity-center-bekannt 2022-07-11T07:20:01+02:00 0.5 https://www.basilea.com/news/news/cresembar-sales-in-asia-pacific-region-trigger-sales-milestone-payment-to-basilea-from-pfizer 2022-08-15T07:20:02+02:00 0.5 https://www.basilea.com/news/news/cresembar-umsaetze-in-der-region-asien-pazifik-loesen-meilensteinzahlung-von-pfizer-an-basilea-aus 2022-08-15T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-approval-for-additional-formulation-of-antifungal-cresembar-isavuconazole-in-china 2022-09-06T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-marktzulassung-fuer-weitere-darreichungsform-fuer-antimykotikum-cresembar-isavuconazol-in-china-bekannt 2022-09-06T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-progress-on-the-implementation-of-its-strategy-to-focus-on-anti-infectives 2022-09-07T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-fortschritte-bei-der-umsetzung-der-strategie-zur-fokussierung-auf-antiinfektiva 2022-09-07T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-positive-results-of-phase-3-eradicate-study-with-ceftobiprole-in-staphylococcus-aureus-bacteremia-sab 2022-09-19T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-positive-ergebnisse-der-phase-3-studie-eradicate-mit-ceftobiprol-bei-staphylococcus-aureus-bakteriaemie-sab-bekannt 2022-09-19T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-zevterar-ceftobiprole-marketing-authorization-in-brazil 2022-09-20T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-marktzulassung-von-zevterar-ceftobiprol-in-brasilien-bekannt 2022-09-20T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-financial-half-year-results-and-progress-in-the-implementation-of-new-anti-infectives-strategy 2022-10-12T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-erzielt-starkes-halbjahresergebnis-und-macht-fortschritte-bei-der-umsetzung-der-neuen-antiinfektiva-strategie 2022-10-12T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-chf-75-million-senior-secured-loan-agreement-with-athyrium-for-non-dilutive-refinancing-of-convertible-bonds-due-in-december-2022 2022-10-23T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vereinbarung-mit-athyrium-ueber-ein-vorrangig-besichertes-darlehen-in-hoehe-von-chf-75-mio-zur-nicht-verwaessernden-refinanzierung-der-im-dezember-2022-faelligen-wandelanleihe-bekannt 2022-10-23T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-sale-of-preclinical-oncology-program-to-nodus-oncology 2022-11-01T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-verkauf-eines-praeklinischen-onkologie-programms-an-nodus-oncology-bekannt 2022-11-01T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-acquisition-of-rights-for-oncology-asset-bal0891-by-sillajen-and-updates-financial-guidance 2022-12-18T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-verkauf-der-rechte-an-onkologie-wirkstoff-bal0891-an-sillajen-bekannt-und-aktualisiert-finanzausblick 2022-12-18T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-closing-of-chf-75-million-senior-secured-loan-agreement-with-athyrium 2022-12-22T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vollzug-closing-der-vereinbarung-mit-athyrium-ueber-vorrangig-besichertes-darlehen-in-hoehe-von-chf-75-mio-bekannt 2022-12-22T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-late-breaking-presentation-on-the-successfully-completed-eradicate-phase-3-study-with-ceftobiprole-in-staphylococcus-aureus-bacteremia-sab-at-idweek-2022 2022-12-27T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-kuendigt-late-breaking-praesentation-der-erfolgreich-abgeschlossenen-phase-3-studie-eradicate-mit-ceftobiprol-bei-staphylococcus-aureus-bakteriaemie-sab-auf-idweek-2022-an 2022-12-27T07:20:01+01:00 0.5 https://www.basilea.com/news/news/eradicate-phase-3-study-results-highlight-the-potential-role-of-ceftobiprole-in-the-treatment-of-staphylococcus-aureus-bacteremia-sab 2023-01-08T07:20:01+01:00 0.5 https://www.basilea.com/news/news/ergebnisse-der-phase-3-studie-eradicate-unterstreichen-die-potenzielle-rolle-von-ceftobiprol-bei-der-behandlung-von-staphylococcus-aureus-bakteriaemie-sab 2023-01-08T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-sale-of-preclinical-oncology-program-to-twentyeight-seven-therapeutics 2023-01-10T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-verkauf-eines-praeklinischen-onkologie-programms-an-twentyeight-seven-therapeutics-bekannt 2023-01-10T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-transition-milestone-for-oncology-asset-bal0891-triggering-milestone-payment-of-usd-4-million-by-sillajen 2023-01-23T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-erreicht-transfer-meilenstein-fuer-onkologie-wirkstoff-bal0891-wodurch-usd-4-mio-meilensteinzahlung-von-sillajen-ausgeloest-wird 2023-01-23T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-regulatory-approval-of-antifungal-cresembar-isavuconazole-in-japan 2023-02-07T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-zulassung-fuer-antimykotikum-cresembar-isavuconazol-in-japan-bekannt 2023-02-07T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-repayment-of-2022-convertible-bonds 2023-02-13T19:24:24+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-rueckzahlung-von-2022er-wandelanleihe-bekannt 2023-02-13T19:24:24+01:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-by-astellas-in-the-us-trigger-chf-20-million-sales-milestone-payment-to-basilea 2023-03-22T07:20:01+01:00 0.5 https://www.basilea.com/news/news/fortgesetzt-gute-cresembar-isavuconazol-verkaufszahlen-von-astellas-in-den-usa-loesen-chf-20-mio-umsatzmeilensteinzahlung-an-basilea-aus 2023-03-22T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-preliminary-2022-revenues-exceeding-guidance-and-provides-portfolio-update 2023-04-17T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vorlaeufige-ueber-der-guidance-liegende-umsatzzahlen-fuer-2022-bekannt-und-informiert-ueber-das-aktuelle-portfolio 2023-04-17T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-preliminary-operating-profit-for-2022-significantly-above-guidance 2023-04-26T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-meldet-fuer-2022-vorlaeufigen-betriebsgewinn-deutlich-ueber-der-guidance 2023-04-26T07:20:01+02:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-second-sales-milestone-payment-to-basilea-from-pfizer 2023-02-08T07:20:01+01:00 0.5 https://www.basilea.com/news/news/fortgesetzt-gute-cresembar-isavuconazol-verkaufszahlen-in-der-region-asien-pazifik-und-china-loesen-zweite-umsatzmeilensteinzahlung-von-pfizer-an-basilea-aus 2023-02-08T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-financial-results-2022-based-on-successful-implementation-of-new-strategy 2023-08-03T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-praesentiert-nach-erfolgreich-implementierter-neuer-strategie-starke-finanzergebnisse-fuer-2022 2023-08-03T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-chf-5-million-milestone-payment-from-asahi-kasei-pharma-for-antifungal-cresembar-isavuconazole-in-japan 2023-03-24T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-von-asahi-kasei-pharma-eine-meilensteinzahlung-in-hoehe-von-chf-5-mio-fuer-das-antimykotikum-cresembar-isavuconazol-in-japan 2023-03-24T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-provides-update-on-new-drug-application-to-the-us-food-and-drug-administration-for-antibiotic-ceftobiprole 2023-04-19T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-informiert-ueber-stand-des-zulassungsantrags-fuer-ceftobiprol-bei-der-us-amerikanischen-arzneimittelbehoerde-food-and-drug-administration 2023-04-19T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting-4 2023-04-27T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-der-generalversammlung-alle-antraege-des-verwaltungsrats-4 2023-04-27T07:20:02+02:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-by-pfizer-trigger-usd-26-million-sales-milestone-payments-to-basilea 2023-06-09T07:20:01+02:00 0.5 https://www.basilea.com/news/news/anhaltend-starke-cresembar-isavuconazol-verkaufszahlen-von-pfizer-loesen-umsatzmeilensteinzahlungen-in-hoehe-von-usd-26-mio-an-basilea-aus 2023-06-09T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-submission-of-a-new-drug-application-to-the-us-food-and-drug-administration-for-its-antibiotic-ceftobiprole 2023-10-18T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-einreichung-eines-zulassungsantrags-bei-der-us-amerikanischen-arzneimittelbehoerde-food-and-drug-administration-fuer-antibiotikum-ceftobiprol-bekannt 2023-10-18T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-revenue-and-profit-growth-in-first-half-year-2023 2023-10-30T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-meldet-starkes-umsatz-und-gewinnwachstum-im-ersten-halbjahr-2023 2023-10-30T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-new-england-journal-of-medicine-publication-of-phase-3-data-on-ceftobiprole-for-the-treatment-of-staphylococcus-aureus-bacteremia 2023-11-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-die-veroeffentlichung-von-phase-3-daten-zu-ceftobiprol-bei-der-behandlung-von-staphylococcus-aureus-bakteriaemie-im-new-england-journal-of-medicine-bekannt 2023-11-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-fda-acceptance-of-new-drug-application-for-antibiotic-ceftobiprole 2023-11-19T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-bekannt-dass-die-fda-den-zulassungsantrag-fuer-das-antibiotikum-ceftobiprol-zur-pruefung-angenommen-hat 2023-11-19T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-new-data-for-ceftobiprole-zevterar-presented-at-us-idweek-congress-2023 2023-10-18T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-neuer-daten-zu-ceftobiprol-zevterar-auf-dem-us-fachkongress-idweek-2023 2023-10-18T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-acquisition-of-novel-clinical-stage-antifungal-for-treatment-of-aspergillus-mold-infections 2023-10-20T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-erwerb-eines-neuartigen-antipilzmittels-in-klinischer-entwicklungsphase-zur-behandlung-von-aspergillus-schimmelpilzinfektionen-bekannt 2023-10-20T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-exclusive-license-and-option-agreement-for-potential-first-in-class-clinical-stage-antibacterial-agent 2024-01-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-exklusive-lizenz-und-optionsvereinbarung-fuer-potenziellen-first-in-class-wirkstoff-in-der-klinischen-entwicklungsphase-gegen-bakterielle-infektionen-bekannt 2024-01-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-acquisition-of-fosmanogepix-a-phase-3-ready-broad-spectrum-antifungal 2024-01-14T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-erwirbt-fosmanogepix-ein-phase-3-bereites-breitspektrum-antipilzmittel 2024-01-14T07:20:01+01:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-third-sales-milestone-payment-for-the-region-from-pfizer-this-year 2024-01-18T07:20:01+01:00 0.5 https://www.basilea.com/news/news/weiterhin-gute-cresembar-isavuconazol-umsaetze-in-der-region-asien-pazifik-und-china-loesen-dritte-meilensteinzahlung-von-pfizer-in-diesem-jahr-fuer-diese-region-aus 2024-01-18T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-that-fda-approves-expanded-use-of-antifungal-cresembar-isavuconazole-in-the-united-states-in-children-with-invasive-aspergillosis-and-invasive-mucormycosis 2024-02-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-fda-zulassung-zur-erweiterten-verwendung-von-antipilzmittel-cresembar-isavuconazol-in-den-usa-bei-kindern-mit-invasiver-aspergillose-und-invasiver-mukormykose-bekannt 2024-02-12T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-accelerated-loan-repayment 2024-03-10T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-kuendigt-beschleunigte-darlehens-rueckzahlung-an 2024-03-10T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-provides-portfolio-status-update 2024-04-03T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-update-zum-stand-des-portfolios 2024-04-03T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-acquisition-of-preclinical-antibiotics-program-from-spexis 2024-04-08T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-erwirbt-praeklinisches-antibiotika-programm-von-spexis 2024-04-08T07:20:01+02:00 0.5 https://www.basilea.com/news/news/cresembar-sales-in-latin-america-trigger-first-sales-milestone-payment-to-basilea 2024-04-24T07:20:02+02:00 0.5 https://www.basilea.com/news/news/cresembar-verkaufszahlen-in-lateinamerika-loesen-erste-umsatzmeilensteinzahlung-an-basilea-aus 2024-04-24T07:20:02+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-2023-full-year-results-with-profitability-significantly-above-guidance-whilst-substantially-expanding-the-rd-portfolio 2024-05-02T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-meldet-starkes-gesamtjahr-2023-mit-einer-ueber-der-guidance-liegenden-profitabilitaet-trotz-substanziell-erweitertem-fe-portfolio 2024-05-02T07:20:01+02:00 0.5 https://www.basilea.com/news/news/continued-strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-milestone-payment-to-basilea 2024-05-15T07:20:01+02:00 0.5 https://www.basilea.com/news/news/anhaltend-gute-cresembar-isavuconazol-umsaetze-in-der-region-asien-pazifik-und-china-loesen-meilensteinzahlung-an-basilea-aus 2024-05-15T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-us-fda-approval-of-antibiotic-zevterar-ceftobiprole-medocaril-for-three-indications 2024-04-05T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-erhalt-der-us-fda-zulassung-fuer-antibiotikum-zevterar-ceftobiprol-medocaril-fuer-drei-indikationen-bekannt 2024-04-05T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-awarded-carb-x-grant-to-develop-recently-acquired-novel-class-of-antibiotics 2024-04-10T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-carb-x-foerderung-fuer-die-entwicklung-einer-kuerzlich-erworbenen-neuen-antibiotika-wirkstoffklasse 2024-04-10T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting-5 2024-04-25T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-der-generalversammlung-alle-antraege-des-verwaltungsrats-5 2024-04-25T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-new-data-for-ceftobiprole-zevterar-at-escmid-global-2024 2024-05-04T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-neuer-daten-zu-ceftobiprol-zevterar-auf-dem-fachkongress-escmid-global-2024 2024-05-04T07:20:01+02:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-milestone-payment-to-basilea 2024-05-17T07:20:01+02:00 0.5 https://www.basilea.com/news/news/starke-cresembar-isavuconazol-umsaetze-in-der-region-asien-pazifik-und-china-loesen-meilensteinzahlung-an-basilea-aus 2024-05-17T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-partners-oncology-drug-candidate-lisavanbulin-with-glioblastoma-foundation 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/basilea-verpartnert-onkologie-wirkstoffkandidat-lisavanbulin-mit-glioblastoma-foundation 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-2024-half-year-results-and-significantly-increases-full-year-revenue-and-profit-guidance 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/basilea-meldet-starke-halbjahresergebnisse-2024-und-erhoeht-signifikant-den-ausblick-fuer-umsatz-und-gewinn-fuer-das-gesamtjahr 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-milestone-payment-to-basilea-1 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/starke-cresembar-isavuconazol-umsaetze-in-der-region-asien-pazifik-und-china-loesen-meilensteinzahlung-an-basilea-aus-1 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/european-commission-decision-to-approve-the-pediatric-use-of-antifungal-cresembar-isavuconazole-and-extension-of-market-exclusivity-triggers-chf-10-million-milestone-payment-to-basilea 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/entscheidung-der-europaeischen-kommission-zur-zulassung-von-antipilzmittel-cresembar-isavuconazol-bei-kindern-und-verlaengerung-der-marktexklusivitaet-loest-chf-10-mio-meilensteinzahlung-an-basilea-aus 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-europe-triggers-usd-25-million-sales-milestone-payment-to-basilea 2024-12-21T07:20:01+01:00 0.5 https://www.basilea.com/news/news/starke-cresembar-isavuconazol-verkaeufe-in-europa-loesen-usd-25-mio-umsatzmeilensteinzahlung-an-basilea-aus 2024-09-11T15:33:31+02:00 0.5 https://www.basilea.com/news/news/basilea-enters-into-agreement-with-barda-to-develop-novel-antifungals-and-antibacterials-and-receives-initial-funding 2024-09-20T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-vereinbarung-mit-barda-zur-entwicklung-neuartiger-medikamente-fuer-die-behandlung-von-infektionen-durch-pilze-und-bakterien-ab-und-erhaelt-erste-foerderung 2024-12-21T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-initiates-clinical-phase-3-study-with-antifungal-fosmanogepix-in-candidemia-and-invasive-candidiasis 2024-09-25T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-initiiert-klinische-phase-3-studie-mit-antipilzmittel-fosmanogepix-bei-candidaemie-und-invasiver-candidiasis 2024-09-25T07:20:01+02:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-fourth-milestone-payment-for-this-region-to-basilea-this-year 2024-12-21T07:20:01+01:00 0.5 https://www.basilea.com/news/news/starke-cresembar-isavuconazol-umsaetze-in-asien-pazifik-und-china-loesen-vierte-meilensteinzahlung-fuer-diese-region-in-diesem-jahr-an-basilea-aus 2024-12-21T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-agreement-with-innoviva-specialty-therapeutics-for-the-commercialization-of-antibiotic-zevterar-ceftobiprole-in-the-united-states 2024-12-17T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-gibt-vereinbarung-mit-innoviva-specialty-therapeutics-zur-vermarktung-von-antibiotikum-zevterar-ceftobiprol-in-den-vereinigten-staaten-bekannt 2024-12-17T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-is-awarded-additional-carb-x-funding-to-develop-new-drug-candidate-from-a-novel-class-of-antibiotics 2024-12-24T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-zusaetzliche-carb-x-foerderung-fuer-die-entwicklung-eines-medikamentenkandidaten-einer-neuen-antibiotika-wirkstoffklasse 2024-12-24T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-provides-portfolio-update-and-outlook 2025-01-18T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-informiert-ueber-stand-seines-portfolios-und-gibt-ausblick 2025-01-18T07:20:01+01:00 0.5 https://www.basilea.com/news/news/strong-sales-growth-for-cresemba-and-zevtera-trigger-further-milestone-payments-to-basilea 2025-01-29T07:20:01+01:00 0.5 https://www.basilea.com/news/news/starkes-verkaufswachstum-von-cresemba-und-zevtera-loest-weitere-meilensteinzahlungen-an-basilea-aus 2025-01-29T07:20:01+01:00 0.5 https://www.basilea.com/news/news/strong-launch-for-cresemba-in-japan-triggers-first-sales-milestone-payment-from-akp-to-basilea 2025-02-06T07:20:01+01:00 0.5 https://www.basilea.com/news/news/starker-verkaufsstart-von-cresemba-in-japan-loest-erste-umsatzmeilensteinzahlung-von-akp-an-basilea-aus 2025-02-06T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-2024-full-year-results-with-significant-increase-in-revenue-profit-and-operating-cash-flow 2025-02-19T07:20:02+01:00 0.5 https://www.basilea.com/news/news/basilea-meldet-fuer-das-gesamtjahr-2024-ein-starkes-ergebnis-mit-deutlichem-anstieg-von-umsatz-gewinn-und-operativem-cashflow 2025-02-19T07:20:02+01:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-milestone-payment-to-basilea-2 2025-03-15T07:20:01+01:00 0.5 https://www.basilea.com/news/news/starke-verkaufszahlen-fuer-cresembar-isavuconazol-in-der-region-asien-pazifik-und-china-loesen-meilensteinzahlung-an-basilea-aus 2025-03-15T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-presentation-of-new-data-for-fosmanogepix-isavuconazole-cresembar-and-ceftobiprole-zevterar-at-escmid-global-2025 2025-04-16T19:28:03+02:00 0.5 https://www.basilea.com/news/news/basilea-berichtet-ueber-praesentation-neuer-daten-zu-fosmanogepix-isavuconazol-cresembar-und-ceftobiprol-zevterar-auf-dem-fachkongress-escmid-global-2025 2025-04-16T19:28:03+02:00 0.5 https://www.basilea.com/news/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting-6 2025-04-17T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-aktionaere-genehmigen-an-der-generalversammlung-alle-antraege-des-verwaltungsrats-6 2025-04-17T07:20:01+02:00 0.5 https://www.basilea.com/news/news/strong-sales-for-cresembar-isavuconazole-in-japan-trigger-second-milestone-payment-from-asahi-kasei-pharma-to-basilea 2025-04-25T07:20:01+02:00 0.5 https://www.basilea.com/news/news/starke-verkaeufe-von-cresembar-isavuconazol-in-japan-loesen-zweite-umsatzmeilensteinzahlung-von-asahi-kasei-pharma-an-basilea-aus 2025-04-25T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-commercial-availability-of-antibiotic-zevterar-ceftobiprole-in-the-united-states 2025-05-21T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-verkaufsstart-seines-antibiotikums-zevterar-ceftobiprol-in-den-usa-bekannt 2025-05-21T07:20:01+02:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-further-milestone-payment-to-basilea 2025-06-06T07:20:01+02:00 0.5 https://www.basilea.com/news/news/starke-verkaufszahlen-fuer-cresembar-isavuconazol-in-der-region-asien-pazifik-und-china-loesen-weitere-meilensteinzahlung-an-basilea-aus 2025-06-06T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-receives-usd-39-million-funding-under-barda-agreement-to-continue-to-advance-novel-antifungals-fosmanogepix-and-bal2062 2025-08-26T08:47:33+02:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-im-rahmen-ihrer-barda-vereinbarung-usd-39-mio-fuer-die-weitere-entwicklung-der-neuen-antipilzmittel-fosmanogepix-und-bal2062 2025-07-09T07:20:01+02:00 0.5 https://www.basilea.com/news/news/basilea-initiates-phase-3-study-with-antifungal-fosmanogepix-in-invasive-mold-infections 2025-09-16T09:24:48+02:00 0.5 https://www.basilea.com/news/news/basilea-initiiert-phase-3-studie-mit-antipilzmittel-fosmanogepix-bei-invasiven-schimmelpilzinfektionen 2025-09-16T09:24:48+02:00 0.5 https://www.basilea.com/news/news/basilea-announces-in-licensing-of-a-novel-clinical-phase-3-ready-oral-antibiotic 2025-09-16T09:24:48+02:00 0.5 https://www.basilea.com/news/news/basilea-gibt-einlizenzierung-eines-neuartigen-oralen-antibiotikums-bekannt-das-bereit-fuer-die-klinische-phase-3-entwicklung-ist 2025-09-16T09:24:48+02:00 0.5 https://www.basilea.com/news/news/basilea-on-track-with-strong-2025-half-year-results 2025-09-16T09:24:48+02:00 0.5 https://www.basilea.com/news/news/basilea-mit-starkem-halbjahresergebnis-2025-auf-kurs 2025-09-16T09:24:48+02:00 0.5 https://www.basilea.com/news/news/basilea-receives-usd-25-million-funding-under-barda-agreement-to-continue-to-advance-novel-antifungals-fosmanogepix-and-bal2062 2026-03-03T14:14:22+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-im-rahmen-ihrer-barda-vereinbarung-usd-25-mio-fuer-die-weitere-entwicklung-der-neuen-antipilzmittel-fosmanogepix-und-bal2062 2026-03-03T14:14:22+01:00 0.5 https://www.basilea.com/news/news/basilea-awarded-barda-contract-for-the-development-of-novel-oral-phase-3-ready-antibiotic-ceftibuten-ledaborbactam 2026-03-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-schliesst-eine-foerdervereinbarung-mit-barda-fuer-die-entwicklung-des-phase-3-bereiten-neuartigen-oralen-antibiotikums-ceftibuten-ledaborbactam-ab 2026-03-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-europe-triggers-usd-30-million-milestone-payment-to-basilea 2026-03-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/starke-verkaufszahlen-fuer-cresembar-isavuconazol-in-europa-loesen-usd-30-mio-meilensteinzahlung-an-basilea-aus 2026-03-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-and-phare-bio-enter-partnership-combining-anti-infectives-industry-expertise-with-unique-ai-capabilities-for-the-development-of-a-novel-antibiotic 2026-03-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-und-phare-bio-gehen-partnerschaft-zur-entwicklung-eines-neuartigen-antibiotikums-ein-kombination-von-industrieller-expertise-und-einzigartigen-ki-faehigkeiten 2026-03-04T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-and-prokaryotics-enter-collaboration-to-develop-a-novel-broad-spectrum-antifungal-for-the-treatment-of-severe-invasive-infections 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-und-prokaryotics-starten-zusammenarbeit-zur-entwicklung-eines-neuartigen-breitband-antipilzmittels-fuer-die-behandlung-schwerer-invasiver-infektionen 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-provides-portfolio-update-and-outlook-1 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-informiert-ueber-stand-seines-portfolios-und-gibt-ausblick-1 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-joins-incate-to-support-antifungal-innovation 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-geht-partnerschaft-mit-incate-ein-um-innovationen-im-bereich-antipilzmittel-zu-unterstuetzen 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-milestone-payment-to-basilea-3 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/gute-verkaufszahlen-fuer-cresembar-isavuconazol-in-der-region-asien-pazifik-und-china-loesen-meilensteinzahlung-an-basilea-aus 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-reports-strong-2025-full-year-results-surpassing-revenue-and-operating-profit-guidance 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-erzielt-starke-ergebnisse-im-geschaeftsjahr-2025-und-uebertrifft-umsatz-und-betriebsgewinn-guidance 2026-02-20T14:48:06+01:00 0.5 https://www.basilea.com/news/news/basilea-receives-further-usd-6-million-from-barda-to-continue-development-of-novel-antibiotic-ceftibuten-ledaborbactam 2026-03-03T14:14:22+01:00 0.5 https://www.basilea.com/news/news/basilea-erhaelt-weitere-usd-6-mio-von-barda-zur-weiterentwicklung-des-neuartigen-antibiotikums-ceftibuten-ledaborbactam 2026-03-03T14:14:22+01:00 0.5 https://www.basilea.com/news/news/basilea-announces-start-of-first-in-human-study-of-novel-antibiotic-bal2420 2026-03-24T07:20:01+01:00 0.5 https://www.basilea.com/news/news/basilea-startet-erste-klinische-studie-am-menschen-fuer-neuartiges-antibiotikum-bal2420 2026-03-24T07:20:01+01:00 0.5